Journal of Clinical PracticeJournal of Clinical PracticeКлиническая практика2220-30952618-8627Eco-Vector68877510.17816/clinpract688775EPUJYXOriginal Study ArticlesОригинальные исследованияResearch ArticleMicroRNA from the blood extracellular microvesicles for minimally invasive diagnostics of lung cancerМикроРНК из внеклеточных микровезикул крови для малоинвазивной диагностики рака лёгкогоhttps://orcid.org/0000-0003-3433-72619752-3241BryzgunovaOlga E.БрызгуноваОльга Евгеньевна
Russian Federation

PhD

канд. биол. наук

biobryz@yandex.ruhttps://orcid.org/0000-0003-2925-93509374-8489KonoshenkoMaria Yu.КоношенкоМария Юрьевна
Russian Federation

PhD

канд. биол. наук

lacyjewelrymk@gmail.comhttps://orcid.org/0009-0004-3004-89693627-2494ShutkoEkaterina V.ШуткоЕкатерина Викторовна
Russian Federation
katshutko@gmail.comhttps://orcid.org/0009-0008-2234-3342ChumakovaViktoria V.ЧумаковаВиктория Викторовна
Russian Federation
v.chumakova@alumni.nsu.ruhttps://orcid.org/0009-0001-3624-23572454-1260MurinaEkaterina A.МуринаЕкатерина Алексеевна
Russian Federation
katyamurina1@gmail.comhttps://orcid.org/0009-0003-9068-5401IlyushchenkoAntonina A.ИлющенкоАнтонина Александровна
Russian Federation
Kdlmedwans@gmail.comhttps://orcid.org/0009-0003-6679-9185DanilovaYaroslava M.ДаниловаЯрослава Михайловна
Russian Federation
yaroslava.danilova.82@mail.ruhttps://orcid.org/0000-0002-8899-42947473-0530GorbunkovStanislav D.ГорбунковСтанислав Дмитриевич
Russian Federation

MD, PhD, Assistant Professor

д-р мед. наук, доцент

sdgorbunkov@mail.ruhttps://orcid.org/0000-0003-3385-26326269-7990ZykovKirill A.ЗыковКирилл Алексеевич
Russian Federation

MD, PhD, Professor member of the Russian Academy of Sciences, corresponding member of the Russian Academy of Sciences

д-р мед. наук, профессор РАН, чл.-корр. РАН

kirillaz@inbox.ruhttps://orcid.org/0000-0003-0687-0894KrasilnikovSergey E.КрасильниковСергей Эдуардович
Russian Federation

MD, PhD

д-р мед. наук

professorkrasilnikov@rambler.ruhttps://orcid.org/0000-0003-3211-51398045-4286KozlovVadim V.КозловВадим Викторович
Russian Federation

MD, PhD, Assistant Professor

д-р мед. наук, доцент

vadimkozlov80@mail.ruhttps://orcid.org/0009-0004-4174-7300LantsukhayYuriy A.ЛанцухайЮрий Александрович
Russian Federation
Lancuh1@mail.ruhttps://orcid.org/0000-0002-0866-02524114-3170LaktionovPavel P.ЛактионовПавел Петрович
Russian Federation

PhD

канд. биол. наук

lakt@1bio.ruInstitute of Chemical Biology and Fundamental MedicineИнститут химической биологии и фундаментальной медициныPulmonology Scientific Research InstituteНаучно-исследовательский институт пульмонологииNovosibirsk National Research State UniversityНовосибирский национальный исследовательский государственный университетFederal Research Center of Fundamental and Translational MedicineФедеральный исследовательский центр фундаментальной и трансляционной медициныNovosibirsk State Medical UniversityНовосибирский государственный медицинский университет08012026050220261647170409202521112025Copyright ©; 2026, Eco-VectorCopyright ©; 2026, Эко-Вектор2026Eco-VectorЭко-Векторhttps://creativecommons.org/licenses/by-nc-nd/4.0https://clinpractice.ru/clinpractice/article/view/688775

BACKGROUND: Asymptomatic development and untimely diagnostics of lung cancer are the main reasons of high mortality caused by this disease. The development of tests based on “fluid biopsy”, which analyze circulating nucleic acids in blood, including the microRNA (miRNA) derived from the microvesicles, can be implemented as an effective screening test for lung cancer assuring the timely detection of the disease. AIM: To analyze the relative expression of 17 miRNAs in the microvesicles fraction from blood plasma samples from patients with non-small-cell lung cancer (NSCLC) and healthy donors. METHODS: The blood plasma microvesicles were isolated by aggregation-precipitation. miRNA was then isolated from the obtained blood microvesicles fraction using the glass fiber filters. Using the method of reverse transcription polymerаse chain reaction, an evaluation was carried out for the diagnostic efficiency of previously proposed miRNA pairs. This analysis was also used to select the most effective diagnostic pairs and panels. RESULTS: The obtained data have confirmed the diagnostic efficiency of four miRNA pairs (-31/-125b; -133b/-374a; -133b/-425; -133b/-222). The sensitivity and the specificity of distinguishing NSCLC patients from donors were 79% and 100%, respectively. Further analysis using paired normalization, compiling the regression models and multiple sample generations yielded three independent minimal panels of miRNA pairs, capable of diagnosing NSCLC with 100% accuracy: (1) -19b/-425, -125b/-378a, -205/-660; (2) -324/-374a, -30e/-92a, -125b/-378a; (3) -324/-374a, -125b/-378a, -205/-660. CONCLUSION: The diagnostic performance of the proposed miRNA panel across independent cohorts, along with the observed inter-cohort variability, supports its promising potential for NSCLC screening test development. These data demonstrate the necessity to identify additional multi-purpose miRNA markers and to validate the panel in further independent patient groups. Such research is essential to establish a reliable and timely miRNA-based screening tool for NSCLC.

Обоснование. Бессимптомное развитие и несвоевременная диагностика рака лёгкого являются основными причинами высокой смертности от этого заболевания. Разработка тестов, основанных на «жидкостной биопсии», т.е. на анализе циркулирующих в крови нуклеиновых кислот, в том числе микроРНК из микровезикул, может позволить реализовать скрининговый тест на рак лёгкого и обеспечить своевременное выявление патологии. Цель исследования — проанализировать относительную экспрессию 17 микроРНК из фракции микровезикул плазмы крови пациентов с немелкоклеточным раком лёгкого и доноров. Методы. Микровезикулы плазмы крови выделены методом агрегации-преципитации, далее из полученной фракции микровезикул крови выделены микроРНК с использованием стекловолокнистых фильтров. С помощью метода полимеразной цепной реакции с обратной транскрипцией оценена диагностическая эффективность ранее предложенных пар микроРНК, а также выбраны наиболее эффективные диагностические пары и панели. Результаты. Полученные данные подтвердили диагностическую эффективность четырёх пар микроРНК (-31/-125b; -133b/-374a; -133b/-425; -133b/-222). Чувствительность и специфичность выявления больных немелкоклеточным раком лёгкого составили 79% и 100% соответственно. Анализ данных экспрессии микроРНК с использованием попарной нормализации, построением регрессионных моделей и многократной генерации выборок позволил сформировать три независимые минимальные панели пар микроРНК, позволяющие с точностью 100% диагностировать больных немелкоклеточным раком лёгкого: (1) -19b/-425, -125b/-378a, -205/-660; (2) -324/-374a, -30e/-92a, -125b/-378a; (3) -324/-374a, -125b/-378a, -205/-660. Заключение. Данные о диагностической эффективности ранее предложенной панели микроРНК маркеров на независимых группах испытуемых и вариабельность данных между независимыми группами испытуемых позволяют надеяться на разработку скрининговых тестов на немелкоклеточный рак лёгкого с использованием микроРНК маркеров. Эти же данные демонстрируют необходимость поиска дополнительных универсальных микроРНК маркеров немелкоклеточного рака лёгкого и дополнительных исследований независимых групп пациентов для уточнения панели маркеров, требуемой для надёжной и своевременной скрининговой диагностики немелкоклеточного рака лёгкого.

non-small-cell lung cancerminimally invasive diagnosticsliquid biopsyextracellular vesiclesmicroRNAreverse transcription polymerase chain reactionRT-PCRнемелкоклеточный рак лёгкогомалоинвазивная диагностикажидкостная биопсиявнеклеточные везикулымикроРНКполимеразная цепная реакция с обратной транскрипциейОТ-ПЦРFederal Medical-Biological Agency of RussiaФедеральное медико-биологическое агентство России388-03-2024-136Ministry of Science And Higher Education of the Russian FederationМинистерство науки и высшего образования Российской Федерации075-03-2025-069The study was funded by the Russian state-funded project for the Pulmonology Scientific Research Institute under FMBA of Russia (grant number 388-03-2024-136) and supported by the Russian state-funded project for ICBFM SB RAS (grant number 125012900932-4).Исследование выполнено в рамках государственного задания № 388-03-2024-136 ФГБУ НИИ пульмонологии ФМБА России и при поддержке государственного задания № 125012900932-4 ИХБФМ СО РАН.Nooreldeen R, Bach H. Current and future development in lung cancer diagnosis. Int J Mol Sci. 2021;22(16):8661. doi: 10.3390/ijms22168661 EDN: WJMDRXPoh KC, Ren TM, Ling GL, et al. Development of a miRNA-based model for lung cancer detection. Cancers (Basel). 2025;17(6):942. doi: 10.3390/cancers17060942 EDN: POOHYYКоношенко М.Ю., Лактионов П.П., Ланцухай Ю.А., и др. Малоинвазивная диагностика рака лёгкого на основе анализа внеклеточной микроРНК крови // Успехи молекулярной онкологии. 2023. Т. 10, № 2. С. 78–89. [Konoshenko MYu, Laktionov PP, Lantsukhai YuA, et al. Cell-free plasma mirnas analysis for low invasive lung cancer diagnostics. Advances in molecular oncology. 2023;10(2):78–89]. doi: 10.17650/2313-805X-2023-10-2-78-89 EDN: FSUWHTCasagrande GM, Silva MO, Reis RM, Leal LF. Liquid biopsy for lung cancer: up-to-date and perspectives for screening programs. Int J Mol Sci. 2023;24(3):2505. doi: 10.3390/ijms24032505 EDN: NARGMHFrydrychowicz M, Kuszel Ł, Dworacki G, Budna-Tukan J. MicroRNA in lung cancer-a novel potential way for early diagnosis and therapy. J Appl Genet. 2023;64(3):459–477. doi: 10.1007/s13353-023-00750-2Shen H, Jin Y, Zhao H, et al. Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer. BMC Med. 2022;20(1):480. doi: 10.1186/s12916-022-02681-x EDN: CZIORYRahat B, Ali T, Sapehia D, et al. Circulating cell-free nucleic acids as epigenetic biomarkers in precision medicine. Front Genet. 2020;11:844. doi: 10.3389/fgene.2020.00844 EDN: GNMMCQRedova M, Sana J, Slaby O. Circulating miRNAs as new blood-based biomarkers for solid cancers. Future Oncol. 2013;9(3):387–402. doi: 10.2217/fon.12.192Andersen GB, Tost J. Circulating miRNAs as biomarker in cancer. Recent Results Cancer Res. 2020;215:277–298. doi: 10.1007/978-3-030-26439-0_15Hao X, Liu Z, Ma F, et al. Exosome-based liquid biopsy in early screening and diagnosis of cancers. Dose Response. 2025;23(2):15593258251344480. doi: 10.1177/15593258251344480Santamaria S, Cardinali B, Rovere M, et al. New insight in early detection and precision medicine in small cell lung cancer: liquid biopsy as innovative clinical tool. Crit Rev Clin Lab Sci. 2025;62(6):404–428. doi: 10.1080/10408363.2025.2493121Kemper M, Krekeler C, Menck K, et al. Liquid biopsies in lung cancer. Cancers (Basel). 2023;15(5):1430. doi: 10.3390/cancers15051430 EDN: USGWWMKonoshenko MY, Lekchnov EA, Bryzgunova OE, et al. The panel of 12 cell-free microRNAs as potential biomarkers in prostate neoplasms. Diagnostics (Basel). 2020;10(1):38. doi: 10.3390/diagnostics10010038 EDN: LYPIHOLekchnov EA, Zaporozhchenko IA, Morozkin ES, et al. Protocol for miRNA isolation from biofluids. Anal Biochem. 2016;499:78–84. doi: 10.1016/j.ab.2016.01.025 EDN: WSKKJFBryzgunova OE, Zaporozhchenko IA, Lekchnov EA, et al. Data analysis algorithm for the development of extracellular miRNA-based diagnostic systems for prostate cancer. PLoS One. 2019;14(4):e0215003. doi: 10.1371/journal.pone.0215003 EDN: DVAYIEKumar MA, Baba SK, Sadida HQ, et al. Extracellular vesicles as tools and targets in therapy for diseases. Signal Transduct Target Ther. 2024;9(1):27. doi: 10.1038/s41392-024-01735-1 EDN: EPOTHGLin J, Wang Y, Zou YQ, et al. Differential miRNA expression in pleural effusions derived from extracellular vesicles of patients with lung cancer, pulmonary tuberculosis, or pneumonia. Tumour Biol. 2016;37(12):15835–15845. doi: 10.1007/s13277-016-5410-6 EDN: WARYQAMüller Bark J, Kulasinghe A, Amenábar JM, Punyadeera C. Exosomes in cancer. Adv Clin Chem. 2021;101:1–40. doi: 10.1016/bs.acc.2020.06.006 EDN: IBIWAZKonoshenko MY, Lekchnov EA, Bryzgunova OE, et al. Isolation of extracellular vesicles from biological fluids via the aggregation-precipitation approach for downstream miRNAs detection. Diagnostics (Basel). 2021;11(3):384. doi: 10.3390/diagnostics11030384 EDN: XGDVRGBryzgunova O, Konoshenko M, Zaporozhchenko I, et al. Isolation of cell-free miRNA from biological fluids: influencing factors and methods. Diagnostics (Basel). 2021;11(5):865. doi: 10.3390/diagnostics11050865 EDN: NNSFYHRoest HP, Ijzermans JN, van der Laan LJ. Evaluation of RNA isolation methods for microRNA quantification in a range of clinical biofluids. BMC Biotechnol. 2021;21(1):48. doi: 10.1186/s12896-021-00706-6 EDN: AIRITCLlorens-Revull M, Martínez-González B, Quer J, et al. Comparison of extracellular vesicle isolation methods for miRNA sequencing. Int J Mol Sci. 2023;24(15):12183. doi: 10.3390/ijms241512183 EDN: IJPAFUAarem J, Brunborg G, Aas KK, et al. Comparison of blood RNA isolation methods from samples stabilized in tempus tubes and stored at a large human biobank. BMC Res Notes. 2016;9(1):430. doi: 10.1186/s13104-016-2224-y EDN: GDFFBRZhang Q, Zheng K, Gao Y, et al. Plasma exosomal miR-1290 and miR-29c-3p as diagnostic biomarkers for lung cancer. Heliyon. 2023;9(10):e21059. doi: 10.1016/j.heliyon.2023.e21059 EDN: PHAFOUSun L, Chen Y, Su Q, et al. Increased plasma miRNA-30a as a biomarker for non-small cell lung cancer. Med Sci Monit. 2016;22:647–655. doi: 10.12659/msm.897330Zheng H, Wu X, Yin J, et al. Clinical applications of liquid biopsies for early lung cancer detection. Am J Cancer Res. 2019;9(12):2567–2579.Sweef O, Zaabout E, Bakheet A, et al. Unraveling therapeutic opportunities and the diagnostic potential of microRNAs for human lung cancer. Pharmaceutics. 2023;15(8):2061. doi: 10.3390/pharmaceutics15082061 EDN: JVJWQWGeng N, Qi Y, Qin W, et al. Two microRNAs of plasma-derived small extracellular vesicles as biomarkers for metastatic non-small cell lung cancer. BMC Pulm Med. 2023;23(1):259. doi: 10.1186/s12890-023-02538-w EDN: OFWUQMLocke WJ, Guanzon D, Ma C, et al. DNA methylation cancer biomarkers: translation to the clinic. Front Genet. 2019;10:1150. doi: 10.3389/fgene.2019.01150 EDN: NLPPCOBibikova M, Fan J. Liquid biopsy for early detection of lung cancer. Chin Med J Pulm Crit Care Med. 2023;1(4):200–206. doi: 10.1016/j.pccm.2023.08.005 EDN: DLEGBJBoeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA. 2011;108(9):3713–3718. doi: 10.1073/pnas.1100048108Jiang Y, Wang W, Tang F, et al. Identifying MiR-140-3p as a stable internal reference to normalize MicroRNA qRT-PCR levels of plasma small extracellular vesicles in lung cancer patients. Genomics. 2024;116(4):110875. doi: 10.1016/j.ygeno.2024.110875 EDN: BOLFDLBryzgunova OE, Zaripov MM, Skvortsova TE, et al. Comparative study of extracellular vesicles from the urine of healthy individuals and prostate cancer patients. PLoS One. 2016;11(6):e0157566. doi: 10.1371/journal.pone.0157566 EDN: WVXOWHGe Q, Zhou Y, Lu J, et al. miRNA in plasma exosome is stable under different storage conditions. Molecules. 2014;19(2):1568–1575. doi: 10.3390/molecules19021568Wang Y, Zhao M, Liu J, et al. miRNA-125b regulates apoptosis of human non-small cell lung cancer via the PI3K/Akt/GSK3β signaling pathway. Oncol Rep. 2017;38(3):1715–1723. doi: 10.3892/or.2017.5808Tang L, Yuan Y, Zhai H, et al. MicroRNA-125b-5p correlates with prognosis and lung adenocarcinoma progression. Front Mol Biosci. 2022;8:788690. doi: 10.3389/fmolb.2021.788690 EDN: OMLEZQYuan H, Su J, Hu S, Wei P. Expression of miR-92a, miR-224 and miR-25 in non-small cell lung cancer and their correlation with clinical characteristics. Am J Transl Res. 2021;13(5):5561–5567.Zhao YL, Zhang JX, Yang JJ, et al. MiR-205-5p promotes lung cancer progression and is valuable for the diagnosis of lung cancer. Thorac Cancer. 2022;13(6):832–843. doi: 10.1111/1759-7714.14331 EDN: XZUVFGPatnaik S, Mallick R, Kannisto E, et al. MiR-205 and MiR-375 microRNA assays to distinguish squamous cell carcinoma from adenocarcinoma in lung cancer biopsies. J Thorac Oncol. 2015;10(3):446–453. doi: 10.1097/JTO.0000000000000423Li ZL, Li D, Yin GQ. MiR-19b-3p promotes tumor progression of non-small cell lung cancer via downregulating HOXA9 and predicts poor prognosis in patients. Histol Histopathol. 2022;37(8):779–789. doi: 10.14670/HH-18-448Wu C, Cao Y, He Z, et al. Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer. Tohoku J Exp Med. 2014;232(2):85–95. doi: 10.1620/tjem.232.85Zhong S, Golpon H, Zardo P, Borlak J. miRNAs in lung cancer. A systematic review identifies predictive and prognostic miRNA candidates for precision medicine in lung cancer. Transl Res. 2021;230:164–196. doi: 10.1016/j.trsl.2020.11.012 EDN: XYLZZBBulgakova O, Zhabayeva D, Kussainova A, et al. miR-19 in blood plasma reflects lung cancer occurrence but is not specifically associated with radon exposure. Oncol Lett. 2018;15(6):8816–8824. doi: 10.3892/ol.2018.8392 EDN: YCEMGDWang Y, Wang L, Guo J, et al. MYPT1, regulated by miR-19b-3p inhibits the progression of non-small cell lung cancer via inhibiting the activation of Wnt/β-catenin signaling. Life Sci. 2021;278:119573. doi: 10.1016/j.lfs.2021.119573 EDN: WCLOKYZhang D, Yang Y, Kang Y, et al. Dysregulated expression of microRNA involved in resistance to osimertinib in EGFR mutant non-small cell lung cancer cells. J Thorac Dis. 2023;15(4):1978–1993. doi: 10.21037/jtd-23-401 EDN: LBJCJLMosca N, Pezzullo M, De Leo I, et al. A novel ceRNET relying on the lncRNA JPX, miR-378a-3p, and its mRNA targets in lung cancer. Cancers (Basel). 2024;16(8):1526. doi: 10.3390/cancers16081526 EDN: SIIZWBCazzoli R, Buttitta F, Di Nicola M, et al. MicroRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol. 2013;8(9):1156–1162. doi: 10.1097/JTO.0b013e318299ac32Chen X, Jiang Y, Huang Z, et al. miRNA-378 reverses chemoresistance to cisplatin in lung adenocarcinoma cells by targeting secreted clusterin. Sci Rep. 2016;6:19455. doi: 10.1038/srep19455Qin Y, Liang R, Lu P, et al. Depicting the implication of miR-378a in cancers. Technol Cancer Res Treat. 2022;21:15330338221134385. doi: 10.1177/15330338221134385 EDN: FTFQPSHo CS, Noor SM, Nagoor NH. MiR-378 and MiR-1827 regulate tumor invasion, migration and angiogenesis in human lung adenocarcinoma by targeting RBX1 and CRKL, respectively. J Cancer. 2018;9(2):331–345. doi: 10.7150/jca.18188 EDN: YDRYZFJi KX, Cui F, Qu D, et al. MiR-378 promotes the cell proliferation of non-small cell lung cancer by inhibiting FOXG1. Eur Rev Med Pharmacol Sci. 2018;22(4):1011–1019. doi: 10.26355/eurrev_201802_14383Li JH, Sun SS, Li N, et al. MiR-205 as a promising biomarker in the diagnosis and prognosis of lung cancer. Oncotarget. 2017;8(54):91938–91949. doi: 10.18632/oncotarget.20262 EDN: YJZZLHDuan B, Guo T, Sun H, et al. MiR-205 as a biological marker in non-small cell lung cancer. Biomed Pharmacother. 2017;91:823–830. doi: 10.1016/j.biopha.2017.04.086Sromek M, Glogowski M, Chechlinska M, et al. Changes in plasma miR-9, miR-16, miR-205 and miR-486 levels after non-small cell lung cancer resection. Cell Oncol (Dordr). 2017;40(5):529–536. doi: 10.1007/s13402-017-0334-8 EDN: YFSDLRLin MH, Chen YZ, Lee MY, et al. Comprehensive identification of microRNA arm selection preference in lung cancer: miR-324-5p and -3p serve oncogenic functions in lung cancer. Oncol Lett. 2018;15(6):9818–9826. doi: 10.3892/ol.2018.8557Ba Z, Zhou Y, Yang Z, et al. MiR-324-5p upregulation potentiates resistance to cisplatin by targeting FBXO11 signalling in non-small cell lung cancer cells. J Biochem. 2019;166(6):517–527. doi: 10.1093/jb/mvz066Ni Y, Zhang W, Mu G, et al. Extracellular RNA profiles in non-small cell lung cancer plasma. J Thorac Dis. 2023;15(5):2742–2753. doi: 10.21037/jtd-23-517 EDN: QUCQJRLarrue R, Fellah S, Boukrout N, et al. MiR-92a-3p regulates cisplatin-induced cancer cell death. Cell Death Dis. 2023;14(9):603. doi: 10.1038/s41419-023-06125-z EDN: BNIGSNZhang X, Wang X, Chai B, et al. Downregulated miR-18a and miR-92a synergistically suppress non-small cell lung cancer via targeting Sprouty 4. Bioengineered. 2022;13(4):11281–11295. doi: 10.1080/21655979.2022.2066755 EDN: EJCZTRReis PP, Drigo SA, Carvalho RF, et al. Circulating miR-16-5p, miR-92a-3p, and miR-451a in plasma from lung cancer patients: potential application in early detection and a regulatory role in tumorigenesis pathways. Cancers (Basel). 2020;12(8):2071. doi: 10.3390/cancers12082071 EDN: OPHZIC